Results for candidaemia translation from English to Maltese

candidaemia only
candidemia biss

candidaemia in non-neutropenic patients
candidaemia f'pazjenti mhux newtropeniċi

candidaemia in non-neutropenic patients.
candidaemia f' pazjenti mhux newtropeniċi.

candidaemia and other forms of invasive candidiasis
candidemia u forom oħra ta’ candidiasis invażiva

treatment of candidaemia in non-neutropenic patients.
kura ta' candidemia f'pazjenti mhux newtropeniċi.

information from clinical studies candidaemia and invasive candidiasis:
23 tagħrif minn studji kliniċi kandidemija u kandidjasi invażiva:

end of iv therapy (1º endpoint) candidaemia only other sterile sitesb c
tmiem tar- iv terapija (l- ewwel endpoint)

ecalta is prescribed to treat a type of fungal infection of the blood called candidaemia.
anidulafungin jingħata sabiex tiġi kkurata tip ta ’ infezzjoni fungali msejjħa candidemia.

56 age) with documented candidaemia were included in the study, of whom 248 were treated with voriconazole.
tliet mija u sebgħin pazjent mhux newtropeniku (ta '' l fuq minn 12- il sena) b' candidaemia dokumentata kienu inklużi fl- istudju, li minnhom 248 ġew ikkurati b' voriconazole.

the study of vfend in the treatment of candidaemia compared vfend with a treatment of amphotericin b followed by fluconazole in 370 patients.
l-istudju ta’ vfend fil-kura ta’ kandidaemija qabbel vfend ma’ kura bl-amfoteriċina b segwita b’kura bil-flukonażol fi 370 pazjent.

the efficacy of voriconazole compared to the regimen of amphotericin b followed by fluconazole in the primary treatment of candidaemia was demonstrated in an open, comparative study.
l- effikaċja ta 'voriconazole f' konfront mar- reġim ta' amphotericin b segwit bi fluconazole fil- kura primarja ta 'candidaemia kienet murija fi studju komparattiv miftuħ.

for candidaemia, the percentage of responders to vfend treatment at the end of therapy was the same as for the comparator (72%).
għal kandidaemija, il-perċentwal ta’ dawk li rrispondew għall-kura b’vfend fi tmiem it-terapija kien l- istess bħal dak tal-komparatur (72%).

the efficacy of ecalta in neutropenic patients with candidaemia and in patients with deep tissue candida infections or intra-abdominal abscess and peritonitis has not been established.
l- effikaċja ta ’ ecalta f’ pazjenti newtropeniċi b’ candidemia u f’ pazjenti b’ infezzjoni candida fit - tessut fond jew b’ axxess intra- addominali u peritonite ma ġietx stabbilita.

candidaemia in non-neutropenic patients the efficacy of voriconazole compared to the regimen of amphotericin b followed by fluconazole in the primary treatment of candidaemia was demonstrated in an open, comparative study.
l- effikaċja ta 'voriconazole f' konfront mar- reġim ta' amphotericin b segwit bi fluconazole fil- kura primarja ta 'candidaemia kienet murija fi studju komparattiv miftuħ.

this represents a heterogeneous population, containing patients with haematological malignancy, hiv infected patients with oesophageal candidiasis and refractory fungal infections, non-neutropenic patients with candidaemia or aspergillosis and healthy volunteers.
din tirrappreżenta popolazzjoni eteroġenea, li tinkludi pazjenti b'tumuri ematoloġiċi, pazjenti infettati bl-hiv b'candidiasis esofagali u infezzjonijiet fungali refrettarji, pazjenti mhux newtropeniċi b'candidaemia jew asperġillosi u voluntiera b'saħħithom.

three studies (one comparative vs fluconazole, two non-comparative) assessed the efficacy of anidulafungin in patients with candidaemia and a limited number of patients with deep tissue candida infections.
tliet studji (wieħed komparattiv vs fluconazole, tnejn mhux komparattivi) evalwaw l- effikaċja ta ’ anidulafungin f’ pazjenti b’ candidemia u numru limitat ta ’ pazjenti oħra b’ infezzjonijiet b’ candida fit - tessut fond.

the most frequent diagnoses were bloodstream infections (candidaemia) (77 %, n = 186) and candida peritonitis (8 %, n = 19); patients with candida endocarditis, osteomyelitis, or meningitis were excluded from this study.
l-aktar sejbiet frekwenti kienu infezzjonijiet fin-nixxiegħa tad-demm (candidaemia) (77 %, n=186) u peritonite candida (8 %, n=19); pazjenti b’endokardite, osteomjelite, jew meninġite candida kienu esklużi minn dan l-istudju.